Summary
Bristol Myers Squibb Company (BMY) announced a change to its Board of Directors, electing Dr. Manuel Hidalgo Medina to serve as a director effective June 1, 2021. This expansion brings the Board size to eleven members. Dr. Hidalgo brings extensive expertise in translational and clinical research, particularly in anticancer drug development and gastrointestinal cancers. His appointment is expected to strengthen the Board's scientific and technological capabilities, especially given his significant experience leading oncology divisions at prominent medical institutions and his role on the Science and Technology Committee. Investors should note that Dr. Hidalgo is considered independent according to NYSE listing standards and the company's own policies. His compensation will align with the company's standard arrangements for non-employee directors, including a cash retainer and deferred share units. This strategic addition suggests a continued focus on innovation and growth within the company's oncology pipeline.
Key Highlights
- 1Election of Dr. Manuel Hidalgo Medina, M.D. to the Board of Directors, effective June 1, 2021.
- 2Board size increased to eleven members.
- 3Dr. Hidalgo possesses over 20 years of experience in anticancer drug development, with a focus on gastrointestinal cancers.
- 4He currently serves as Chief of Hematology and Medical Oncology at Weill Cornell Medicine and New York Presbyterian/Weill Cornell Medical Center.
- 5Dr. Hidalgo will serve as a member of the Science and Technology Committee.
- 6The Board has determined Dr. Hidalgo is independent under NYSE and company standards.
- 7Standard compensation for non-employee directors will be provided, including a $100,000 annual retainer and $190,000 in deferred share units.